Global Antihistamine Drugs Market – Industry Trends and Forecast to 2031

항히스타민제 시장 분석 및 규모

항히스타민제 시장은 최근 몇 년 동안 알레르기 반응에서 히스타민의 역할에 대한 이해가 증가함에 따라 급속한 성장을 이룰 것으로 예상됩니다. 과민 반응의 중요한 매개체인 히스타민은 혈관 확장, 근육 수축, 염증 및 부종에 기여합니다. 항히스타민제는 히스타민 1형(H1) 수용체를 차단하여 알레르기와 관련된 증상을 효과적으로 완화합니다. 세계보건기구의 "알레르기 백서 2011-2012"에 따르면 알레르기성 비염은 전 세계 인구의 10%~30%에 영향을 미치는 반면 두드러기 유병률은 전 세계적으로 20%를 넘습니다. 알레르기 유병률이 높고 젊은 개인 사이에서 발생률이 증가함에 따라 예측 기간 동안 항히스타민제 소비가 급증할 것으로 예상됩니다.

글로벌 항히스타민제 시장 규모는 2023년에 2억 7,996만 달러로 평가되었으며, 2031년까지 5억 6,816만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 9.25%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

시장 정의

항히스타민제는 재채기, 가려움증, 눈물, 콧물과 같은 알레르기 증상을 완화하는 데 일반적으로 사용되는 약물입니다. 이 약물은 알레르기 반응 중에 신체에서 방출되는 화학 물질인 히스타민의 작용을 차단하여 작용합니다 . 히스타민은 히스타민 수용체에 결합하여 다양한 알레르기 증상을 유발하는 역할을 합니다. 항히스타민제는 알레르기 증상을 줄이거나 예방하여 알레르기, 건초열 또는 기타 알레르기 질환을 앓고 있는 개인에게 완화를 제공합니다. 이러한 약물은 경구 정제, 비강 스프레이 , 점안액 및 국소 크림을 포함한 다양한 형태로 제공되며 다양한 알레르기 관련 증상과 선호도에 맞게 제공됩니다.

항히스타민제 시장 동향

운전자

• 알레르기 반응의 증가로 항히스타민제에 대한 수요가 증가

알레르기성 비염 , 두드러기, 알레르기성 결막염과 같은 알레르기 질환을 겪는 사람이 늘어나면서 효과적인 증상 완화에 대한 수요가 증가하고 있습니다. 항히스타민제는 가려움증, 재채기, 비강 충혈, 피부 발진과 같은 증상을 완화하여 이러한 질환을 관리하는 데 중요한 역할을 합니다. 알레르기와 사용 가능한 치료 옵션에 대한 인식이 확대되고 항히스타민 제형과 전달 방법이 발전함에 따라 이러한 약물 시장은 전 세계 알레르기 환자의 증가하는 건강 관리 요구를 충족하기 위해 지속적으로 성장할 준비가 되었습니다.

예를 들어,

2023년 3월, Astepro Allergy와 Meghann Fahy의 전략적 협력은 알레르기의 세계적 증가에 대처하려는 의지를 강조합니다. 이 협력은 알레르기 증상을 완화하는 데 효과적인 빠르게 작용하는 비강 스프레이인 Astepro에 대한 인지도와 접근성을 높이는 것을 목표로 합니다. 이 협력은 Fahy의 플랫폼을 활용하여 알레르기로 고통받는 개인에게 적시에 완화를 제공하여 항히스타민제 약물 시장의 성장에 더욱 기여하고자 합니다.

• 첨단 기술 개발에 대한 투자 증가로 항히스타민제 혁신이 증가

Technological advancements enhance the research and development process, leading to the discovery of more effective and targeted antihistamine therapies. Improved drug delivery systems, such as nano-encapsulation and controlled-release formulations, enhance the efficacy and convenience of antihistamine medications, thereby expanding their market potential. Furthermore, advancements in diagnostic tools and genetic testing enable personalized medicine approaches, allowing for tailored antihistamine treatments based on individual patient profiles. The synergy between technological innovation and pharmaceutical development fosters growth and innovation in the antihistamine drugs market, meeting the evolving needs of patients with allergic conditions.

For Instance,

In January 2022, Antares Pharma's announcement of positive Phase I results for ATRS-1902 highlights the impact of technological advancements on the Addison's Disease Drugs Market. ATRS-1902's development represents an innovation in targeted drug delivery systems for treating acute adrenal insufficiency, aligning with the trend toward more precise and convenient management of the condition. This advancement underscores the potential for improved patient outcomes and increased demand for specialized treatments in the market.

Opportunities

• Rise of Emerging Markets due to Expanding Consumer Base Enhancing the Reach of Antihistamine Medications

As economies develop and healthcare infrastructure improves in various regions, there is a growing awareness and demand for pharmaceuticals to address allergic conditions. Antihistamine drugs, with their established efficacy in managing allergies, stand to benefit from this trend. Furthermore, factors such as urbanization, environmental changes, and increased exposure to allergens contribute to the rising prevalence of allergic disorders in emerging markets. Pharmaceutical companies can capitalize on this expanding consumer base by introducing affordable and accessible antihistamine products tailored to the specific needs of these markets, thereby driving growth and market penetration.

• Rising Development of Biological Antihistamines Increases its Demand among the Consumers

Antihistamines medications, also known as biologics, are engineered from living organisms and target specific components of the immune system involved in allergic reactions, such as histamine receptors or inflammatory mediators. Unsuch as traditional antihistamines, biological antihistamines offer targeted and potentially more effective treatment options with fewer side effects. They offer a chance for enhanced management of allergic conditions, especially in individuals who may not exhibit sufficient response to conventional antihistamines or who encounter notable side effects. The development of biological antihistamines opens avenues for personalized medicine approaches, catering to the individualized needs of patients with allergies and related conditions.

Restraints/Challenges

• Rising Side Effects of Antihistamine Drugs Reduces Patient Compliance

While these medications effectively alleviate allergy symptoms by blocking histamine receptors, they can also induce adverse reactions. Common side effects include drowsiness, dizziness, dry mouth, blurred vision, and constipation, particularly with first-generation antihistamines. Additionally, some individuals may experience paradoxical reactions, such as agitation or excitability, especially in children and the elderly. These side effects can lead to reduced patient compliance and reluctance to use antihistamine medications, thereby impacting market growth.

• Regulatory Challenges Limits the Product Availability

Stringent regulations governing drug approval processes, labeling requirements, and safety standards can significantly impact the development, manufacturing, and commercialization of antihistamine medications. Compliance with regulatory guidelines often requires substantial investments in research, clinical trials, and documentation, leading to prolonged timelines and increased costs for market entry. Moreover, variations in regulatory requirements across different regions and countries necessitate careful navigation and adaptation by pharmaceutical companies, further complicating market access and expansion efforts. These regulatory hurdles can impede innovation, limit product availability, and hinder market growth within the antihistamine drugs sector.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In December 2022, Morepen Laboratories Limited received approval from the U.S. FDA for fexofenadine hydrochloride, marketed under the brand 'Allerga.' This anti-allergy medication is used to alleviate symptoms associated with allergies and hay fever, enhancing the company's portfolio for addressing allergic conditions in the U.S. market
• In June 2021, The U.S. FDA granted approval for Astepro (azelastine hydrochloride nasal spray, 0.15 percent) to be available over the counter for individuals aged six and above. This represents a significant milestone in allergy treatment, providing nonprescription access to a nasal antihistamine for managing seasonal and perennial allergic rhinitis, commonly known as allergies
• In June 2020, Cadila Pharmaceuticals launched Bilastin syrup and tablets in India, expanding the options for allergy treatment in the country. Bilastin, an anti-allergic medication, is specifically indicated for the management of allergic rhinitis, contributing to the company's efforts in addressing the healthcare needs of individuals suffering from allergic conditions in the Indian market

Antihistamine Drugs Market Scope

The market is segmented on the basis of type, indication, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.

Type

• Prescription-based
• Over-the-counter (OTC)

Indication

• Urticaria
• Allergy
• Dermatitis
• Others

Dosage Form

• Tablets
• Capsules
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

 Antihistamine Drugs Market Regional Analysis/Insights

The market is analyzed, and market size insights and trends are provided by country, type, indication, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East & Africa.

North America is expected to dominate the market due to several factors. Major key players in the pharmaceutical industry are increasingly investing in innovative technologies, driving advancements in drug development and distribution. Additionally, the region's substantial healthcare expenditure indicates a strong commitment to medical research and treatment, fostering a conducive environment for market growth. These combined factors are expected to propel North America's dominance in the antihistamine drugs market, positioning it at the forefront of global advancements in allergy and inflammation management.

The Asia-Pacific is expected to experience significant growth due to the rising incidence of allergic reactions in the population. This trend is expected to drive demand for healthcare services and products tailored to allergy management. Moreover, ongoing advancements in healthcare infrastructure across the region will play a pivotal role in facilitating access to diagnosis, treatment, and prevention services, thereby accelerating the growth trajectory of the market in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Antihistamine Drugs Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Akorn Operation Company LLC (U.S.)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline(U.K.)
• Novartis AG (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Boehringer Ingelheim International GmbH. (Germany)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Prestige Consumer Healthcare Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• Almirall, S.A (Spain)
• Zenomed Healthcare Private Limited (India)
• Cadila Pharmaceuticals (India)

SKU-53442